Boltz, an AI drug design company spun out of MIT, has raised $110 million in a Series A round led by Bessemer Venture Partners. The company announced the deal on November 18, 2026.
The round comes about ten months after Boltz raised a $28 million seed round in January. Boltz did not disclose a valuation.
Boltz Series A funding: deal terms and investors
Bessemer led the round, with partners Andrew Hedin and Byron Deeter working on the deal. Returning backers include Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures.
New investors in the Boltz funding round include Greycroft, F-Prime Capital, Hummingbird and lab software company Benchling.
| Detail | Boltz Series A |
|---|---|
| Amount | $110 million |
| Lead investor | Bessemer Venture Partners |
| Announced | November 18, 2026 |
| Valuation | Not disclosed |
| Previous round | $28 million seed (January 2026) |
| Total disclosed funding | $138 million |
The Series A is nearly four times the size of the seed round. Amplify, a16z and Zetta led that earlier round, and Hugging Face CEO Clem Delangue was among its backers.
What Boltz builds for drug discovery
Gabriele Corso, Jeremy Wohlwend and Saro Passaro founded Boltz. All three worked in Regina Barzilay’s research group at MIT before turning the project into a public benefit corporation on January 8, 2026.
Corso is the CEO.
Open-source Boltz models
The team released Boltz-1 in November 2024. The model predicts how proteins and other molecules fold and fit together, and the team said it matched the accuracy of Google DeepMind’s AlphaFold 3.
Boltz-2 added a prediction of the binding strength between a molecule and its target. A third open model, BoltzGen, handles protein design.
According to Bessemer, the open models have passed 5 million downloads and reach more than 100,000 scientists.
Proprietary models and Boltz Lab
On June 16, 2026, Boltz launched two paid models. BoltzMol-1 finds small-molecule drug candidates and confirmed hits on six of 10 difficult targets after testing 28 to 51 compounds per target.
BoltzProt-1 designs proteins. It nearly tripled the BoltzGen hit rate on nanobody design.
Scientists run these models through Boltz Lab, a platform launched with the seed round. Customers pay in “molecular tokens,” buying usage as each experiment needs it.
An API also lets AI coding agents such as Claude Code, Codex and Gemini call the models.
Boltz usage growth and pharma partners
Molecular token usage on Boltz grew 50-fold between June and November. Usage reached about eight times the June level by August, passed 25 times in late October and hit 50 times on November 8.
Six of the world’s 20 largest drug companies now work with Boltz, including Pfizer, GSK, Takeda and Bristol Myers Squibb. The Pfizer deal is a multi-year collaboration announced alongside the January launch.
How Boltz plans to use the $110 million
Boltz will spend the new capital on computing capacity, data and hiring, according to The Pharma Letter. The company employs about 40 scientists and engineers.
Corso has said the next generation of Boltz models already produces better molecules than the current releases.
Boltz funding and the AI drug discovery market
The Boltz round landed one day after Isomorphic Labs announced a $5 billion Series C. Isomorphic’s earlier $2.1 billion round ranked among the biggest AI funding rounds of Q2 2026.
Chai Discovery, which also builds AI models for molecular design, raised a $400 million Series C in July at a $3.8 billion valuation. Both companies appear on AI Funding Tracker’s list of top AI healthcare startups by valuation and funding.
| Company | Round | Amount | Announced |
|---|---|---|---|
| Isomorphic Labs | Series C | $5 billion | November 17, 2026 |
| Chai Discovery | Series C | $400 million | July 14, 2026 |
| Boltz | Series A | $110 million | November 18, 2026 |
Boltz is at an earlier stage than both companies. It sells access to its models by usage, while Isomorphic is moving its own drug candidates toward clinical trials.
FAQ
How much did Boltz raise in its Series A?
Boltz raised $110 million in a Series A round announced on November 18, 2026. Bessemer Venture Partners led the round.
Total disclosed funding now stands at $138 million.
Who invested in the Boltz funding round?
Bessemer led the round. Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures returned, while Greycroft, F-Prime Capital, Hummingbird and Benchling joined as new investors.
What does Boltz do?
Boltz builds AI models that predict molecular structures and design proteins and small-molecule drugs. It offers open-source models plus paid models through its Boltz Lab platform.
What is the Boltz valuation?
Boltz has not disclosed a valuation for its Series A round.
Which pharma companies work with Boltz?
Six of the world’s 20 largest drug companies are partners, including Pfizer, GSK, Takeda and Bristol Myers Squibb. Pfizer signed a multi-year collaboration in January 2026.